Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy

Daniel J. Landsburg; Emily C. Ayers; David A. Bond; Kami J. Maddocks; Reem Karmali; Amir Behdad; Madeira Curry; Nina D. Wagner-Johnston; Dipenkumar Modi; Radhakrishnan Ramchandren; Sarit E. Assouline; Rawan Faramand; Julio C. Chavez; Pallawi Torka; Angel Mier Hicks; L. Jeffrey Medeiros; Shaoying Li

doi:10.1111/bjh.16319

Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy

Daniel J. Landsburg^*, Emily C. Ayers, David A. Bond, Kami J. Maddocks, Reem Karmali, Amir Behdad, Madeira Curry, Nina D. Wagner-Johnston, Dipenkumar Modi, Radhakrishnan Ramchandren, Sarit E. Assouline, Rawan Faramand, Julio C. Chavez, Pallawi Torka, Angel Mier Hicks, L. Jeffrey Medeiros, Shaoying Li

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.

Original language	English (US)
Pages (from-to)	313-317
Number of pages	5
Journal	British Journal of Haematology
Volume	189
Issue number	2
DOIs	https://doi.org/10.1111/bjh.16319
State	Published - Apr 1 2020

Keywords

chemotherapy
fluorescence in situ hybridization
molecular diagnosis
non-Hodgkin lymphoma

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.16319

Cite this

Landsburg, D. J., Ayers, E. C., Bond, D. A., Maddocks, K. J., Karmali, R., Behdad, A., Curry, M., Wagner-Johnston, N. D., Modi, D., Ramchandren, R., Assouline, S. E., Faramand, R., Chavez, J. C., Torka, P., Mier Hicks, A., Medeiros, L. J., & Li, S. (2020). Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. British Journal of Haematology, 189(2), 313-317. https://doi.org/10.1111/bjh.16319

@article{8a207adba3364311acc8171d282f317d,

title = "Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy",

abstract = "While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.",

keywords = "chemotherapy, fluorescence in situ hybridization, molecular diagnosis, non-Hodgkin lymphoma",

author = "Landsburg, {Daniel J.} and Ayers, {Emily C.} and Bond, {David A.} and Maddocks, {Kami J.} and Reem Karmali and Amir Behdad and Madeira Curry and Wagner-Johnston, {Nina D.} and Dipenkumar Modi and Radhakrishnan Ramchandren and Assouline, {Sarit E.} and Rawan Faramand and Chavez, {Julio C.} and Pallawi Torka and {Mier Hicks}, Angel and Medeiros, {L. Jeffrey} and Shaoying Li",

note = "Publisher Copyright: {\textcopyright} 2019 British Society for Haematology and John Wiley & Sons Ltd",

year = "2020",

month = apr,

day = "1",

doi = "10.1111/bjh.16319",

language = "English (US)",

volume = "189",

pages = "313--317",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

Landsburg, DJ, Ayers, EC, Bond, DA, Maddocks, KJ, Karmali, R, Behdad, A, Curry, M, Wagner-Johnston, ND, Modi, D, Ramchandren, R, Assouline, SE, Faramand, R, Chavez, JC, Torka, P, Mier Hicks, A, Medeiros, LJ & Li, S 2020, 'Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy', British Journal of Haematology, vol. 189, no. 2, pp. 313-317. https://doi.org/10.1111/bjh.16319

Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. / Landsburg, Daniel J.; Ayers, Emily C.; Bond, David A. et al.
In: British Journal of Haematology, Vol. 189, No. 2, 01.04.2020, p. 313-317.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy

AU - Landsburg, Daniel J.

AU - Ayers, Emily C.

AU - Bond, David A.

AU - Maddocks, Kami J.

AU - Karmali, Reem

AU - Behdad, Amir

AU - Curry, Madeira

AU - Wagner-Johnston, Nina D.

AU - Modi, Dipenkumar

AU - Ramchandren, Radhakrishnan

AU - Assouline, Sarit E.

AU - Faramand, Rawan

AU - Chavez, Julio C.

AU - Torka, Pallawi

AU - Mier Hicks, Angel

AU - Medeiros, L. Jeffrey

AU - Li, Shaoying

PY - 2020/4/1

Y1 - 2020/4/1

N2 - While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.

AB - While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.

KW - chemotherapy

KW - fluorescence in situ hybridization

KW - molecular diagnosis

KW - non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85076284357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076284357&partnerID=8YFLogxK

U2 - 10.1111/bjh.16319

DO - 10.1111/bjh.16319

M3 - Article

C2 - 31804715

AN - SCOPUS:85076284357

SN - 0007-1048

VL - 189

SP - 313

EP - 317

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this